obs Physicians | LucenceINSIGHT™ 路胜因思康™

LucenceINSIGHT™
For Healthcare Providers

LucenceINSIGHT™ is a multi-cancer early detection (MCED) tool that screens for the signal of multiple cancers in a simple blood draw.

Leveraging proprietary amplicon-based technology to screen for the signal of cancer with a sensitivity of 80.9% and a specificity of 99%¹, the test identifies single nucleotide variations (SNVs), indels and cancer associated viruses such as Epstein-Barr virus (EBV) and Human Papillomavirus (HPV) in circulating tumor DNA (ctDNA).

Utilizing data from the analysis, a localization signal is derived and used to predict up to 2 sites where the cancer signal might have originated from. LucenceINSIGHT™ lists these findings as Predicted Signal Localization.

With a prediction accuracy of 88%¹, the Predicted Signal Localization helps guide further confirmatory diagnostic testing.

Cancers covered by LucenceINSIGHT™

There are 50 cancer types covered by LucenceINSIGHT™ PLUS. LucenceINSIGHT™ covers the 12 cancers highlighted in orange.

Providing INSIGHT to your patients

Offering LucenceINSIGHT™ at your healthcare facility begins simply with a quick introduction from our patient excellence team.

If you would like to find out more about LucenceINSIGHT™, fill up this form here and we will get in touch with you shortly.

Email Us

Frequently Asked Questions For Physicians

LucenceINSIGHT™ uses proprietary amplicon-based next-generation sequencing (NGS) technology to screen for the signal of 50 cancers with a sensitivity of 80.9% and specificity of 99%. The test identifies single nucleotide variations (SNVs), indels and cancer associated viruses such as Epstein-Barr virus (EBV) and Human Papillomavirus (HPV) in circulating tumor DNA (ctDNA).

When a cancer-associated finding is made, the machine-learning algorithm analyzes the data to predict up to 2 sites where the cancer signal might have originated from. The report will present the result as Predicted Signal Localization, with an accuracy of 88%.

LucenceINSIGHT™ investigates alterations that are found in the genes. Genes are instructions for the cells to grow and function and changes (mutations) to the genes sometimes cause the growth functions to go out of control, leading to cancer.

Cancer marker tests such as CA19-9 or CA125 look for the presence of proteins which are made in higher amounts by cancer cells.

Overall, gene mutations and protein markers have a ‘cause and effect’ relationship when it comes to cancer detection. LucenceINSIGHT™ should be used in addition to routine cancer screening tools offered by your healthcare provider to bring clarity in early cancer screening.

References

Data on file.

SINGAPORE OFFICE

211 Henderson Rd #04-02
Henderson Industrial Park
Singapore 159552

sales.asean@lucence.com
+65 6592 5102

HONG KONG OFFICE

Rooms 05-15, 13A/F, South Tower World Finance Centre Harbour City,
17 Canton Road, Tsim Sha Tsui, Kowloon Hong Kong

sales.hk@lucence.com
+852 5182 7199